Serum 1,5-anhydroglucitol levels in patients with fulminant type 1 diabetes are lower than those in patients with type 2 diabetes |
| |
| Authors: | Masafumi Koga Jun Murai Hiroshi Saito Mikio Mukai Soji Kasayama Akihisa Imagawa Toshiaki Hanafusa |
| |
| Affiliation: | 1. Department of Internal Medicine, Kinki Central Hospital, Hyogo, Japan;2. Department of Medicine, Nissay Hospital, Osaka, Japan;3. Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Osaka, Japan;4. First Department of Internal Medicine, Osaka Medical College, Osaka, Japan;1. Yale University School of Medicine, New Haven, Conn;2. Whiteley Clinic, Guildford, Surrey, United Kingdom;3. Faculty of Health and Medical Sciences, University of Surrey, Guildford, Surrey, United Kingdom;4. Vascular Insights LLC, Madison, Conn;1. Department of Medical Oncology, Klinikum Grosshadern and Comprehensive Cancer Center, Ludwig-Maximilians-Universität München, Munich, Germany;2. German Cancer Consortium (DKTK), 69120 Heidelberg, Germany;3. German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany;4. Institute of Pathology, Ludwig-Maximilians-Universität München, Munich, Germany;5. Munich Cancer Registry (MCR), Klinikum Grosshadern, Ludwig-Maximilians-Universität München, Munich, Germany;6. Institute of Medical Informatics, Biometry and Epidemiology (IBE), Ludwig-Maximilians-Universität München, Munich, Germany;1. Wayne State University School of Medicine, 540 E. Canfield Ave., Detroit, MI 48201, USA;2. Department of Pathology, Northwestern Memorial Hospital, 251 E. Huron, Chicago, IL 60611, USA;3. Department of Ophthalmology, Northwestern Memorial Hospital, 251 E. Huron, Chicago, IL 60611, USA |
| |
| Abstract: | ObjectivesWe investigated clinical relevance of serum 1,5-anhydroglucitol (1,5-AG) levels in fulminant type 1 diabetes mellitus (FT1DM) patients, because 1,5-AG is known to reflect short term glycemic control.Design and methodsSubjects comprised 7 patients with FT1DM and 32 patients with type 2 diabetes mellitus (T2DM) with HbA1c < 8.5%. All of them have never been treated for diabetes.ResultsHbA1C showed no significant difference between both groups. On the other hand, serum 1,5-AG levels were significantly lower in the FT1DM patients than in the T2DM patients. Serum 1,5-AG levels were < 5.0 μg/ml in 6 of 7 (86%) FT1DM patients, compared with only 1 of 32 (3%) T2DM patients.ConclusionsSerum 1,5-AG levels were lower in the FT1DM patients than in the T2DM patients. Serum 1,5-AG, but not HbA1C, reflects short-term exacerbation of glycemia in patients with FT1DM. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
